ArticleAmerican journal of cancer research2023
Survival benefit of metastasectomy in first-line cetuximab therapy in patients with RAS wild-type metastatic colorectal cancer: a nationwide registry.
Article in American journal of cancer research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 6 citations in OpenAlex.
- Correspondence for the article titled - "Prognostic impact of metastatic sites and its metastasectomy in colorectal cancer: a retrospective analysis from a single institution".International journal of colorectal disease · 2026Article
- Optimizing third-line and beyond therapies for metastatic colorectal cancer in Taiwan: an evidence-based consensus.Therapeutic advances in medical oncology · 2026Article
- Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Locally Advanced Rectal Cancer Treated with Neoadjuvant Concurrent Chemoradiotherapy and Robotic-Assisted Resection.Oncology research · 2026Article
- Differential effects of theWorld journal of gastrointestinal surgery · 2025Article
- Prognostic impact of metastatic sites and its metastasectomy in colorectal cancer: a retrospective analysis from a single institution.International journal of colorectal disease · 2025Article
- Efficacy and safety of first-line cetuximab therapy for older patients (aged ≥ 70 years) withAmerican journal of cancer research · 2025Article
- Efficacy and safety of regorafenib plus FOLFIRI withTherapeutic advances in medical oncology · 2025Article
- Impact on survival benefits of asymptomatic primary tumor resection after bevacizumab plus FOLFIRI as first-line therapy for patients with metastatic colorectal cancer with synchronous unresectable metastasis.International journal of colorectal disease · 2024Article
- Outcomes of upfront primary tumor resection in patients with synchronousAmerican journal of cancer research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This multicenter study aimed to explore the survival benefit of metastasectomy by first-line cetuximab-based chemotherapy in real-world patients with
Indexed as
Identifiers
38187069PMC10767339W4390689822What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.